ZUNVEYL (benzgalantamine gluconate)
ZUNVEYL is indicated for the treatment of Alzheimer's Disease; Dementia.
How ZUNVEYL Works
ZUNVEYL acts as a prodrug of galantamine, which is a competitive and reversible inhibitor of the enzyme acetylcholinesterase. It works by increasing the concentration of acetylcholine in the brain by preventing its breakdown, or hydrolysis, by cholinesterase. This process enhances cholinergic function, which is often diminished in Alzheimer's disease due to the degeneration of specific neurons. The drug's impact may diminish over time as the disease advances and fewer cholinergic neurons remain functionally intact.
Details
- Status
- Prescription
- First Approved
- 2024-07-26
- Patent Cliff
- 2045
- Routes
- ORAL
- Dosage Forms
- TABLET, DELAYED RELEASE
ZUNVEYL Approval History
What ZUNVEYL Treats
2 indicationsZUNVEYL is approved for 2 conditions since its original approval in 2024. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Alzheimer's Disease
- Dementia
ZUNVEYL Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Direct competitors
Same target(s) AND same indication — head-to-head.
MoA expansion candidates
Same target(s), different indications — where else is this mechanism being explored?
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to ZUNVEYL
3 of 10FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
ZUNVEYL FDA Label Details
Indications & Usage
FDA Label (PDF)ZUNVEYL is indicated for the treatment of Alzheimer's Disease; Dementia.
ZUNVEYL Patents & Exclusivity
Patents (4 active)
Pro Intelligence Preview
Deep insights for ZUNVEYL
Revenue Insights
- • Quarterly revenue tracking
- • Historical trend analysis
Patent Timeline
- • Cliff: 2045
- • 36 active patents
Trial Analysis
- • Clinical trial tracking
- • Development stage analysis
Competitive Landscape
- • 10 similar drugs
- • Same target/indication analysis
Full approval history • All patents • Revenue trends • Competitor analysis
Related Intelligence
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.